FDA meeting on epinephrine
This article was originally published in The Tan Sheet
Executive Summary
FDA announces a Dec. 5 public meeting to solicit comments on a proposed rule to amend the agency's regulation on the use of ozone-depleting substances in self-pressurized containers to "remove the essential-use designation for oral pressurized metered-dose inhalers containing epinephrine." In addition, the comment period on the proposed rule published in September is being extended to Dec. 19, FDA says (1"The Tan Sheet" Sept. 24, 2007, p. 7). Meeting attendees must register by Nov. 23, according to the agency...
You may also be interested in...
Primatene Mist To Be Unavailable After 2010 – Proposed Rule
Wyeth will allow its epinephrine-containing Primatene Mist metered-dose inhaler to be phased out of the market after 2010, rather than reformulating to comply with an FDA proposed rule published in the Sept. 20 Federal Register
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.